Galecto Inc (GLTO)

$29.78 -0.22 (-0.73%)
Market Cap 47.92M
Revenue (ttm) 0.00
Net Income (ttm) -21.44M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 262,100
Avg Vol 158,876
Day's Range N/A - N/A
Shares Out 1.60M
Stochastic %K 80%
Beta 1.42
Analysts Strong Sell
Price Target $46.75

Company Profile

Galecto, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 70 52 10
Website: galecto.com
Address:
Ole Maaloes Vej 3, Copenhagen N, Copenhagen, Denmark
BillionerOfKing
BillionerOfKing Feb. 23 at 2:57 PM
$GLTO Current Stock Price: $30.25
0 · Reply
UgoGreg
UgoGreg Feb. 22 at 9:28 PM
$GLTO https://youtu.be/nCPt9XhiRxk
0 · Reply
UgoGreg
UgoGreg Feb. 22 at 5:57 PM
$GLTO https://youtu.be/VcWJkTGHJVM
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 1:38 PM
$GLTO RSI: 62.19, MACD: 1.0196 Vol: 2.75, MA20: 26.07, MA50: 26.08 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 2:45 AM
$GLTO RSI: 62.19, MACD: 1.0196 Vol: 2.75, MA20: 26.07, MA50: 26.08 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
MillionTrader_xy
MillionTrader_xy Feb. 18 at 1:13 PM
$SNSE $GLTO Move incoming https://www.businesswire.com/news/home/20260217234993/en/Sensei-Biotherapeutics-Announces-Acquisition-of-Faeth-Therapeutics-and-%24200-Million-Concurrent-Private-Placement
0 · Reply
TinyTiger19
TinyTiger19 Feb. 17 at 6:47 PM
$UTI $GLTO $BETR $ATEX _
0 · Reply
MochiMeerkat
MochiMeerkat Feb. 17 at 4:15 PM
$IFBD $GLTO $GVH $VRT __<
0 · Reply
erevnon
erevnon Feb. 17 at 3:13 PM
Guggenheim maintains Galecto $GLTO at Buy and raises the price target from $36 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
notreload_ai
notreload_ai Feb. 17 at 3:00 PM
$GLTO , $KRRO ... William Blair boosts Korro Bio to Outperform with favorable risk/reward, while UBS starts Galecto at Buy with a $45 target on its promising blood disorder therapy. https://notreload.xyz/analyst-upgrades-boost-two-biotech-stocks-korro-bio-galecto/
0 · Reply
Latest News on GLTO
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million

Feb 12, 2026, 4:01 PM EST - 11 days ago

Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million

Galecto Announces Pricing of $275 Million Underwritten Public Offering

Feb 10, 2026, 10:42 PM EST - 12 days ago

Galecto Announces Pricing of $275 Million Underwritten Public Offering

Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 16, 2025, 5:00 PM EST - 2 months ago

Galecto, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GLTO, MOVE: two penny stocks quadrupled today – but should you buy?

Nov 10, 2025, 1:08 PM EST - 3 months ago

GLTO, MOVE: two penny stocks quadrupled today – but should you buy?

MOVE

Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029

Nov 10, 2025, 11:47 AM EST - 3 months ago

Galecto Stock Soars: Strengthens Blood Cancer Pipeline With Damora Therapeutics Deal, Secures Fresh Funding To 2029

Galecto Announces Acquisition of Damora Therapeutics

Nov 10, 2025, 7:00 AM EST - 3 months ago

Galecto Announces Acquisition of Damora Therapeutics

Galecto Reports Third Quarter 2025 Operating and Financial Results

Nov 6, 2025, 4:30 PM EST - 3 months ago

Galecto Reports Third Quarter 2025 Operating and Financial Results

What's Going On With Nano-Cap Galecto Stock On Tuesday?

Oct 7, 2025, 1:05 PM EDT - 4 months ago

What's Going On With Nano-Cap Galecto Stock On Tuesday?

Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble

Oct 7, 2025, 10:27 AM EDT - 4 months ago

Galecto stock skyrockets 600%: why tiny float stocks are market's latest gamble

Galecto Reports Second Quarter 2025 Operating and Financial Results

Aug 5, 2025, 4:15 PM EDT - 7 months ago

Galecto Reports Second Quarter 2025 Operating and Financial Results

Galecto Reports First Quarter 2025 Operating and Financial Results

May 8, 2025, 4:30 PM EDT - 10 months ago

Galecto Reports First Quarter 2025 Operating and Financial Results

Galecto Reports Full-Year 2024 Financial Results

Mar 19, 2025, 4:45 PM EDT - 1 year ago

Galecto Reports Full-Year 2024 Financial Results

Galecto to Participate in Upcoming Investor Conferences

Feb 6, 2025, 8:00 AM EST - 1 year ago

Galecto to Participate in Upcoming Investor Conferences

Galecto Reports Third Quarter 2024 Financial Results

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Galecto Reports Third Quarter 2024 Financial Results

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Oct 7, 2024, 8:45 AM EDT - 1 year ago

Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

Galecto Announces Reverse Stock Split

Aug 28, 2024, 9:00 AM EDT - 1 year ago

Galecto Announces Reverse Stock Split

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

May 1, 2024, 4:01 PM EDT - 1 year ago

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Dec 21, 2023, 4:05 PM EST - 2 years ago

Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Oct 23, 2023, 8:00 AM EDT - 2 years ago

Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial

Galecto Announces Plans to Explore Strategic Alternatives

Sep 26, 2023, 4:01 PM EDT - 2 years ago

Galecto Announces Plans to Explore Strategic Alternatives

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

Sep 14, 2023, 8:15 AM EDT - 2 years ago

Galecto Biotech Collapse: Opportunity For Galectin Therapeutics

GALT

Galecto to Present at Investor Conferences in September

Aug 31, 2023, 11:00 AM EDT - 2 years ago

Galecto to Present at Investor Conferences in September

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Aug 15, 2023, 8:39 AM EDT - 2 years ago

Galecto shares drop 65% as biotech halts development of lung-disease treatment

Galecto to discontinue development of lung disease treatment

Aug 15, 2023, 7:55 AM EDT - 2 years ago

Galecto to discontinue development of lung disease treatment

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Aug 15, 2023, 7:30 AM EDT - 2 years ago

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Galecto Reports Second Quarter Operating and Financial Results

Jul 31, 2023, 4:05 PM EDT - 2 years ago

Galecto Reports Second Quarter Operating and Financial Results

Galecto Set to Join Russell Microcap® Index

Jun 20, 2023, 8:58 AM EDT - 2 years ago

Galecto Set to Join Russell Microcap® Index

Galecto to Present at the Upcoming Jefferies Healthcare Conference

May 30, 2023, 8:00 AM EDT - 2 years ago

Galecto to Present at the Upcoming Jefferies Healthcare Conference

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

May 23, 2023, 8:30 AM EDT - 2 years ago

Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139 in Idiopathic Pulmonary Fibrosis

Galecto to Present Poster at Upcoming ATS 2023 International Conference

May 17, 2023, 4:01 PM EDT - 3 years ago

Galecto to Present Poster at Upcoming ATS 2023 International Conference

Galecto Reports First Quarter Operating and Financial Results

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Galecto Reports First Quarter Operating and Financial Results

Galecto: Promising Pipeline And Excellent Risk-Reward

Apr 18, 2023, 7:01 PM EDT - 3 years ago

Galecto: Promising Pipeline And Excellent Risk-Reward

Galecto to Present Two Posters at AACR Annual Meeting 2023

Apr 13, 2023, 8:30 AM EDT - 3 years ago

Galecto to Present Two Posters at AACR Annual Meeting 2023

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

Mar 9, 2023, 7:00 AM EST - 3 years ago

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Mar 2, 2023, 4:05 PM EST - 3 years ago

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Galecto to Participate in SVB Securities Global Biopharma Conference

Feb 1, 2023, 8:00 AM EST - 3 years ago

Galecto to Participate in SVB Securities Global Biopharma Conference

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

Dec 7, 2022, 4:05 PM EST - 3 years ago

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

Galecto Reports Third Quarter Operating and Financial Results

Nov 8, 2022, 9:15 AM EST - 3 years ago

Galecto Reports Third Quarter Operating and Financial Results

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Nov 8, 2022, 6:00 AM EST - 3 years ago

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

Galecto to Participate in Jefferies London Healthcare Conference

Nov 3, 2022, 8:00 AM EDT - 3 years ago

Galecto to Participate in Jefferies London Healthcare Conference

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Oct 19, 2022, 8:00 AM EDT - 3 years ago

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

Oct 17, 2022, 6:00 AM EDT - 3 years ago

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

Galecto ($GLTO) Phase 2a Trial Reduces Fibrosis of Bone Marrow in Patients with Myelofibrosis

Sep 29, 2022, 10:11 AM EDT - 3 years ago

Galecto ($GLTO) Phase 2a Trial Reduces Fibrosis of Bone Marrow in Patients with Myelofibrosis

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

Sep 29, 2022, 6:00 AM EDT - 3 years ago

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022, 8:30 AM EDT - 3 years ago

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

Aug 29, 2022, 8:30 AM EDT - 3 years ago

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

Galecto to Participate at Jefferies Healthcare Conference

May 31, 2022, 8:30 AM EDT - 4 years ago

Galecto to Participate at Jefferies Healthcare Conference

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

May 26, 2022, 8:30 AM EDT - 4 years ago

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

BillionerOfKing
BillionerOfKing Feb. 23 at 2:57 PM
$GLTO Current Stock Price: $30.25
0 · Reply
UgoGreg
UgoGreg Feb. 22 at 9:28 PM
$GLTO https://youtu.be/nCPt9XhiRxk
0 · Reply
UgoGreg
UgoGreg Feb. 22 at 5:57 PM
$GLTO https://youtu.be/VcWJkTGHJVM
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 1:38 PM
$GLTO RSI: 62.19, MACD: 1.0196 Vol: 2.75, MA20: 26.07, MA50: 26.08 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 19 at 2:45 AM
$GLTO RSI: 62.19, MACD: 1.0196 Vol: 2.75, MA20: 26.07, MA50: 26.08 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
MillionTrader_xy
MillionTrader_xy Feb. 18 at 1:13 PM
$SNSE $GLTO Move incoming https://www.businesswire.com/news/home/20260217234993/en/Sensei-Biotherapeutics-Announces-Acquisition-of-Faeth-Therapeutics-and-%24200-Million-Concurrent-Private-Placement
0 · Reply
TinyTiger19
TinyTiger19 Feb. 17 at 6:47 PM
$UTI $GLTO $BETR $ATEX _
0 · Reply
MochiMeerkat
MochiMeerkat Feb. 17 at 4:15 PM
$IFBD $GLTO $GVH $VRT __<
0 · Reply
erevnon
erevnon Feb. 17 at 3:13 PM
Guggenheim maintains Galecto $GLTO at Buy and raises the price target from $36 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
notreload_ai
notreload_ai Feb. 17 at 3:00 PM
$GLTO , $KRRO ... William Blair boosts Korro Bio to Outperform with favorable risk/reward, while UBS starts Galecto at Buy with a $45 target on its promising blood disorder therapy. https://notreload.xyz/analyst-upgrades-boost-two-biotech-stocks-korro-bio-galecto/
0 · Reply
OpenOutcrier
OpenOutcrier Feb. 13 at 2:08 PM
$GLTO (-9.7% pre) Galecto Prices $275 Mln Public Offering At $19 Per Share, Stock Down https://ooc.bz/l/93366
0 · Reply
PurpleGains
PurpleGains Feb. 13 at 3:26 AM
$GLTO over 30..32 is a given..real move happens upon the break of that level.. nothing stopping it to 35+.. a dip to 27 area would be gift ...
0 · Reply
turk123
turk123 Feb. 13 at 1:19 AM
$GLTO 🧐
0 · Reply
turk123
turk123 Feb. 13 at 1:19 AM
$GLTO 🧌
0 · Reply
turk123
turk123 Feb. 13 at 1:19 AM
$GLTO 🚨
0 · Reply
turk123
turk123 Feb. 13 at 1:19 AM
$GLTO …..
0 · Reply
turk123
turk123 Feb. 13 at 1:19 AM
$GLTO …
0 · Reply
turk123
turk123 Feb. 13 at 1:19 AM
$GLTO ..
0 · Reply
turk123
turk123 Feb. 13 at 1:19 AM
$GLTO .
0 · Reply
turk123
turk123 Feb. 13 at 1:18 AM
$GLTO get in before losses too high $PINS $AMAT
0 · Reply
turk123
turk123 Feb. 13 at 1:17 AM
$GLTO going $75 tomorroe
0 · Reply
turk123
turk123 Feb. 13 at 1:17 AM
$GLTO stocks dont move like this for no reason
0 · Reply